Stock Track | Mesoblast Soars 5.12% Intraday on FDA BLA Filing Number for Rexlemestrocel-L Heart Failure Therapy

Stock Track

07/01

MESOBLAST LTD (MSB.AU) shares soared 5.12% during intraday trading on Wednesday, driven by a significant regulatory milestone for its lead therapy candidate.

The biotech company announced it received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration for rexlemestrocel-L. The therapy is intended to prevent gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD).

Mesoblast also requested a modular review of the BLA, a process that can potentially expedite the regulatory pathway. The therapy holds both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation, which support eligibility for rolling or priority review by the FDA, highlighting the treatment's potential to address an unmet medical need.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1174776615"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174776615\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174776615?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-01 11:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174776615","market":"nz","top_or_hot":-1,"title":"Stock Track | Mesoblast Soars 5.12% Intraday on FDA BLA Filing Number for Rexlemestrocel-L Heart Failure Therapy","media":"Stock Track","content":"<p>MESOBLAST LTD (MSB.AU) shares soared 5.12% during intraday trading on Wednesday, driven by a significant regulatory milestone for its lead therapy candidate.</p><p>The biotech company announced it received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration for rexlemestrocel-L. The therapy is intended to prevent gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD).</p><p>Mesoblast also requested a modular review of the BLA, a process that can potentially expedite the regulatory pathway. The therapy holds both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation, which support eligibility for rolling or priority review by the FDA, highlighting the treatment's potential to address an unmet medical need.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mesoblast Soars 5.12% Intraday on FDA BLA Filing Number for Rexlemestrocel-L Heart Failure Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mesoblast Soars 5.12% Intraday on FDA BLA Filing Number for Rexlemestrocel-L Heart Failure Therapy\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-07-01 11:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>MESOBLAST LTD (MSB.AU) shares soared 5.12% during intraday trading on Wednesday, driven by a significant regulatory milestone for its lead therapy candidate.</p><p>The biotech company announced it received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration for rexlemestrocel-L. The therapy is intended to prevent gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD).</p><p>Mesoblast also requested a modular review of the BLA, a process that can potentially expedite the regulatory pathway. The therapy holds both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation, which support eligibility for rolling or priority review by the FDA, highlighting the treatment's potential to address an unmet medical need.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MSB.AU","symbol_name":"MESOBLAST LTD","start_time":0,"source_url":"","article_id":"1174776615","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174776615","pubTimestamp":1782877717,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MESOBLAST LTD (MSB.AU) shares soared 5.12% during intraday trading on Wednesday, driven by a significant regulatory milestone for its lead therapy candidate.The biotech company announced it received...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MSB.AU":"MESOBLAST LTD"},"translate_title":"股票追踪|Mesoblast盘中大涨5.12%Rexlemestrocel-L心衰疗法FDA BLA备案号","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB.AU":1},"content_text":"MESOBLAST LTD (MSB.AU) shares soared 5.12% during intraday trading on Wednesday, driven by a significant regulatory milestone for its lead therapy candidate.The biotech company announced it received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration for rexlemestrocel-L. The therapy is intended to prevent gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD).Mesoblast also requested a modular review of the BLA, a process that can potentially expedite the regulatory pathway. The therapy holds both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation, which support eligibility for rolling or priority review by the FDA, highlighting the treatment's potential to address an unmet medical need.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}